Temozolomide for the treatment of malignant glioma

Published on 16 Oct 2017
Last Updated on 16 Oct 2017

Guidance Recommendation

The Ministry of Health's Drug Advisory Committee has recommended:

• Temozolomide 20mg and 100mg capsules in line with their registered indications for the treatment of:

  • Newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment, and

  • Malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Subsidy status

Generic temozolomide 20mg and 100mg capsules are recommended for inclusion on the Standard Drug List (SDL).

Temozolomide (16 Oct 2017) [PDF, 447 KB]